These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22976135)

  • 21. [Cilengitide: a new weapon against glioblastoma?].
    Tumori; 2008; 94(5):suppl 1-2. PubMed ID: 19112962
    [No Abstract]   [Full Text] [Related]  

  • 22. Adhesion molecules and the extracellular matrix as drug targets for glioma.
    Shimizu T; Kurozumi K; Ishida J; Ichikawa T; Date I
    Brain Tumor Pathol; 2016 Apr; 33(2):97-106. PubMed ID: 26992378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy of cilengitide with belotecan against experimental glioblastoma.
    Kim YH; Lee JK; Kim B; DeWitt JP; Lee JE; Han JH; Kim SK; Oh CW; Kim CY
    Int J Cancer; 2013 Aug; 133(3):749-56. PubMed ID: 23354807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
    Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrins in glioblastoma: Still an attractive target?
    Paolillo M; Serra M; Schinelli S
    Pharmacol Res; 2016 Nov; 113(Pt A):55-61. PubMed ID: 27498157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
    Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
    Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of anti-angiogenic therapy for malignant glioma.
    Reardon DA; Desjardins A; Rich JN; Vredenburgh JJ
    Curr Treat Options Oncol; 2008 Feb; 9(1):1-22. PubMed ID: 18256938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cilengitide Merck.
    Smith JW
    Curr Opin Investig Drugs; 2003 Jun; 4(6):741-5. PubMed ID: 12901235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery.
    Zhao YZ; Lin Q; Wong HL; Shen XT; Yang W; Xu HL; Mao KL; Tian FR; Yang JJ; Xu J; Xiao J; Lu CT
    J Control Release; 2016 Feb; 224():112-125. PubMed ID: 26792571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cilengitide induces autophagy-mediated cell death in glioma cells.
    Lomonaco SL; Finniss S; Xiang C; Lee HK; Jiang W; Lemke N; Rempel SA; Mikkelsen T; Brodie C
    Neuro Oncol; 2011 Aug; 13(8):857-65. PubMed ID: 21788343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.
    Lautenschlaeger T; Perry J; Peereboom D; Li B; Ibrahim A; Huebner A; Meng W; White J; Chakravarti A
    Radiat Oncol; 2013 Oct; 8():246. PubMed ID: 24153102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
    Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
    Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-angiogenic therapy in glioma.
    Butowski N
    Clin Transl Oncol; 2011 May; 13(5):294-300. PubMed ID: 21596656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
    Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
    Tentori L; Dorio AS; Muzi A; Lacal PM; Ruffini F; Navarra P; Graziani G
    Oncol Rep; 2008 Apr; 19(4):1039-43. PubMed ID: 18357394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
    Batich KA; Sampson JH
    Expert Opin Pharmacother; 2014 Oct; 15(14):2047-61. PubMed ID: 25139628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiogenesis and invasion in glioma.
    Onishi M; Ichikawa T; Kurozumi K; Date I
    Brain Tumor Pathol; 2011 Feb; 28(1):13-24. PubMed ID: 21221826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.